SCHEMBL14938599

SCHEMBL14938599

Cc1ccn[c]c1CN1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 6/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ MBTD1 Q05BQ5 1/20 0.37
▸ L3MBTL3 Q96JM7 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ HRH4 Q9H3N8 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ NCF1 P14598 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ LTA4H P09960 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14938652 0.85 CYP2A13 (0.47) HRH3L3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL14938597 0.76 ALDH1A1 (0.42) HRH3CHRNB2CHRNA4L3MBTL1TDP1
SCHEMBL10555530 0.71 — —
SCHEMBL14938797 0.70 ALDH1A1 (0.42) HRH3L3MBTL1MBTD1L3MBTL3TDP1
SCHEMBL14941441 0.69 CHKA (0.36) L3MBTL1TDP1ALDH1A1CYP1A2KDM4E
SCHEMBL1854026 0.67 CYP2C19 (0.46) HRH3CHRNB2CHRNA4L3MBTL1MBTD1
SCHEMBL9851324 0.66 HPGD (0.37) L3MBTL1TDP1ALDH1A1CYP1A2CYP3A4
SCHEMBL14938658 0.66 CHKA (0.32) ALDH1A1CYP1A2KDM4EMEN1KMT2A
SCHEMBL14938595 0.66 — —
SCHEMBL10525457 0.64 HRH3 (0.50) HRH3CHRNB2CHRNA4L3MBTL1MBTD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48622-E1 Therapeutically active pyrazolo-pyrimidine derivatives UCB Biopharma SRL (BE) 2021-07-06 — — US disclosed
EP-3157922-B1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2018-11-28 — — EP disclosed
EP-3386984-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-10-17 — — EP disclosed
US-10087180-B2 Pyrazolo-pyridine derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-02 — — US disclosed
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-07-19 — — US disclosed
US-10000497-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BY) 2018-06-19 — — US disclosed
US-9969748-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-05-15 — — US disclosed
EP-2935269-B1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2018-04-11 — — EP disclosed
US-9714248-B2 Therapeutically active pyrazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2017-07-25 — — US disclosed
WO-2017097871-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2017-06-15 — — WO disclosed
US-20160194329-A1 Therapeutically Active Pyrazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2016-07-07 — — US disclosed
WO-2015193168-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
WO-2015193167-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
WO-2015193169-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
EP-2935269-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB Biopharma SPRL (BE) 2015-10-28 — — EP disclosed
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed
EP-2776445-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB Pharma, S.A. (BE) 2014-09-17 — — EP disclosed
WO-2014096423-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2014-06-26 — — WO disclosed
WO-2013068458-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors PI4KB, PI4KA, PI4K2B HRH3 1916/4885CHRNB2 4238/4885CHRNA4 4046/4885
US-20160194329-A1 Therapeutically Active Pyrazolo-Pyrimidine Derivatives HAVCR2, TPMT, NFATC1 HRH3 2098/4885CHRNB2 4773/4885CHRNA4 4508/4885
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 HRH3 3779/4885CHRNB2 4410/4885CHRNA4 4475/4885
US-10087180-B2 Pyrazolo-pyridine derivatives as kinase inhibitors PI4KA, PI4KB, PI4K2A HRH3 2486/4885CHRNB2 4611/4885CHRNA4 3297/4885
US-10000497-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors PI4KB, PI4KA, PI4K2B HRH3 1669/4885CHRNB2 4352/4885CHRNA4 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback